Publication:
Chloroqine Treatment of Severe Malaria in Children

dc.contributor.authorNicholas J. Whiteen_US
dc.contributor.authorKirk D. Milleren_US
dc.contributor.authorFrederick C. Churchillen_US
dc.contributor.authorCarol Berryen_US
dc.contributor.authorJudith Brownen_US
dc.contributor.authorSharyon B. Williamsen_US
dc.contributor.authorBrian M. Greenwooden_US
dc.contributor.otherMahidol Universityen_US
dc.date.accessioned2018-06-14T09:08:36Z
dc.date.available2018-06-14T09:08:36Z
dc.date.issued1988-12-08en_US
dc.description.abstractAlthough empirical regimens of parenteral chloroquine have been used extensively to treat severe malaria for 40 years, recent recommendations state that parenteral chloroquine should no longer be used because of potential toxicity. We studied prospectively the pharmacokinetics and toxicity of seven chloroquine regimens in 58 Gambian children with severe chloroquine-sensitive falciparum malaria. In all regimens the total cumulative dose was 25 mg of chloroquine base per kilogram of body weight. Chloroquine was rapidly absorbed after either intramuscular or subcutaneous administration (5 mg of base per kilogram every 12 hours), producing high peak blood concentrations but transient hypotension in 5 of 18 patients (28 percent). Intermittent intravenous infusion (5 mg of base per kilogram over 4 hours, repeated every 12 hours) also produced wide fluctuations in chloroquine levels, suggesting incomplete distribution from a small central compartment. Continuous infusion (0.83 mg of base per kilogram per hour for 30 hours) and smaller, more frequent intramuscular or subcutaneous injections of chloroquine (3.5 mg of base per kilogram every 6 hours) produced smoother blood-concentration profiles with lower early peak levels and no adverse cardiovascular or neurologic effects. Chloroquine given by nasogastric tube (initial dose, 10 mg of base per kilogram) was absorbed well, even in comatose children. We conclude that simple alterations in dosage and frequency of administration can give parenteral chloroquine an acceptable therapeutic ratio and reinstate it as the treatment of choice for severe malaria in areas where chloroquine resistance is not a major problem. (N Engl J Med 1988;319:1493–500). © 1988, Massachusetts Medical Society. All rights reserved.en_US
dc.identifier.citationNew England Journal of Medicine. Vol.319, No.23 (1988), 1493-1500en_US
dc.identifier.doi10.1056/NEJM198812083192301en_US
dc.identifier.issn15334406en_US
dc.identifier.issn00284793en_US
dc.identifier.other2-s2.0-0024271233en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/15585
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=0024271233&origin=inwarden_US
dc.subjectMedicineen_US
dc.titleChloroqine Treatment of Severe Malaria in Childrenen_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=0024271233&origin=inwarden_US

Files

Collections